Dr. Patrick Soon-Shiong, Founder, Chairman
Dr. Patrick Soon‐Shiong a physician, surgeon and scientist, has pioneered novel therapies for both diabetes and cancer, published over 100 scientific papers, and has over 95 issued patents on groundbreaking advancements spanning myriad fields.
Dr. Soon‐Shiong performed the world’s first encapsulated human islet transplant, the first engineered islet cell transplant and the first pig to man islet cell transplant in diabetic patients. He invented and developed Abraxane, the nation’s first FDA approved protein nanoparticle albumin‐bound delivery technology for the treatment of cancer. Abraxane was approved by the FDA for metastatic breast cancer in 2005, lung cancer in 2012, and pancreatic cancer in 2013. In 2014 Phase 3 trials revealed a 48 percent pathological complete remission in triple negative breast cancer with Abraxane treatment prior to surgery. Abraxane is now approved in many countries across the globe and sales are expected to reach a billion dollars in 2016. The drug is approved in the U.S. and E.U. for metastatic breast cancer, lung cancer and advanced pancreatic cancer, making it the only drug of its kind.
From 1997 to 2010 Dr. Soon‐Shiong has served as founder, Chairman and CEO of two global pharmaceutical companies, American Pharmaceutical Partners and Abraxis BioScience. Both were acquired for multi‐billion dollars in 2008 and 2010. In 2011 he founded NantWorks, an ecosystem of companies to create a transformative global health information and next generation pharmaceutical development network, for the secure sharing of genetic and medical information ‐ empowering doctors to treat patients with proven precision at the first point of care and, ultimately, improving the lives of individuals, everywhere.
Dr. Soon‐Shiong serves as Chairman of the Chan Soon‐Shiong Family Foundation and Chairman and CEO of the Chan Soon‐Shiong Institute of Molecular Medicine, a non‐profit medical research organization. He currently co‐chairs the CEO Council for Health and Innovation at the Bipartisan Policy Center and is a member of the Global Advisory Board of Bank of America. He is an Adjunct Professor of Surgery at UCLA, a visiting Professor at the Imperial College of London, and Dartmouth College. The Friends of the National Library of Medicine has honored him with their Distinguished Medical Science Award.
Zaw Soe, Executive Vice President of Engineering
Zaw brings an impressive 20 years of experience in analog design and semiconductor industry to lead the versatile engineering organization at Tensorcom. Prior to Tensorcom, Zaw worked 7 years at Realtek Semiconductor leading distributed engineering teams to develop Bluetooth PHYs, IEEE 802.11a/b/g compliant WLAN transceiver, and Ultra Wideband PHYs. After joining Tensorcom in 2011, Zaw has been applying his extensive technical and management skills to lead the Tensorcom Engineering team in developing the first low power, all CMOS, 60GHz SoC that enables wireless gigabit communications for a wide range of mobile, embedded, and handheld devices.
Zaw has authored or co-authored 10 patents issued or pending in the areas of high speed DACs, PLL tuning, I/Q compensation, and Spread Spectrum Modulation. He also is the holder of 7 issued patents dealing specifically with 60GHz RF. He earned a BSEE from Drexel University and a MSEE from University of Pennsylvania, Philadelphia.